Biotech - Spark Newswire

3 minute read

Puma Biotechnology Announces Publication Of Phase II Clinical Trial Of Alisertib In JAMA Oncology

March 14, 8:31 AM

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with

PBYI

1 minute read

Synaffix Has Announced The Expansion Of Its License Agreement With Macrogenics Adding Up To Four Antibody-drug Conjugates Programs; Expanded Collaboration Includes Up To $2.2B In Total Potential Payments

By Benzinga Newsdesk

March 14, 8:19 AM

The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion, plus tiered low to high single-digit royalties on potential net

MGNX

1 minute read

Atea Pharmaceuticals Announced The Presentation Of New Phase 1, In Vitro And In Vivo Data That Demonstrate Key Profile Attributes Of Atea’s Lead Drug Candidate, Bemnifosbuvir, For Covid-19 And Hepatitis C

By Benzinga Newsdesk

March 14, 7:18 AM

Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies Bemnifosbuvir retains activity against all SARS-CoV-2 variants of concern evaluated as well as

AVIR

1 minute read

Enanta Pharmaceuticals To Present New Data For EDP-235 In Development As An Oral, Once-daily Treatment For Covid-19, At The International Conference On Antiviral Research

By Benzinga Newsdesk

March 14, 7:16 AM

Phase 1 Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Supportive of Once-Daily Dosing Without Ritonavir Preclinical Animal Data Indicate the Potential for EDP-235 to Reduce Household

ENTA

2 minute read

Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?

By Shanthi Rexaline

March 14, 5:41 AM

Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr.

BNTX

2 minute read

Reported Late Monday March 13, Everest Medicines Announces Partner Calliditas Therapeutics Reports Topline Results From Phase 3 NefIgArd Trial Evaluating Nefecon In IgA Nephropathy; Trial Primary Endpoint Was Met With Nefecon

By Happy Mohamed

March 14, 1:10 AM

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX)))) ("Calliditas") reported

CALT

1 minute read

Reported Late Monday March 13, Reunion Neuroscience Files Lawsuit Against Mindset Pharma Alleging That Mindset Knowingly Copied Reunion’s RE104 Compound And Misleadingly Presented That Exact Composition To The Patent Office As Mindset’s Invention

By Happy Mohamed

March 14, 12:59 AM

Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion"

REUN

1 minute read

Reported Late Monday March 13, Innoviva Announces FDA Advisory Committee Meeting To Review Sulbactam-Durlobactam An Investigational Targeted Antibiotic On April 17, 2023

By Happy Mohamed

March 14, 12:57 AM

Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration's (FDA)

INVA

2 minute read

Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken

By Vandana Singh

March 13, 2:03 PM

Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts were immaterial to their operations.

BGNE

1 minute read

Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation

By Vandana Singh

March 13, 1:18 PM

Bristol Myers Squibb & Co’s (NYSE:BMY) Eliquis, Pfizer Inc’s (NYSE:PFE) Ibrance, and AbbVie Inc’s (NYSE:ABBV) Imbruvica are expected to be among the ten…

ABBV